JP2018534595A5 - - Google Patents

Download PDF

Info

Publication number
JP2018534595A5
JP2018534595A5 JP2018543010A JP2018543010A JP2018534595A5 JP 2018534595 A5 JP2018534595 A5 JP 2018534595A5 JP 2018543010 A JP2018543010 A JP 2018543010A JP 2018543010 A JP2018543010 A JP 2018543010A JP 2018534595 A5 JP2018534595 A5 JP 2018534595A5
Authority
JP
Japan
Prior art keywords
configuration
genomic
gene
cnv
configurations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018543010A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018534595A (ja
JP7043412B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/059877 external-priority patent/WO2017079139A1/en
Publication of JP2018534595A publication Critical patent/JP2018534595A/ja
Publication of JP2018534595A5 publication Critical patent/JP2018534595A5/ja
Application granted granted Critical
Publication of JP7043412B2 publication Critical patent/JP7043412B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018543010A 2015-11-03 2016-11-01 疾患の不均一性を特徴づけるための転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞ゲノムプロファイリング Active JP7043412B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562250422P 2015-11-03 2015-11-03
US62/250,422 2015-11-03
PCT/US2016/059877 WO2017079139A1 (en) 2015-11-03 2016-11-01 Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity

Publications (3)

Publication Number Publication Date
JP2018534595A JP2018534595A (ja) 2018-11-22
JP2018534595A5 true JP2018534595A5 (https=) 2019-11-28
JP7043412B2 JP7043412B2 (ja) 2022-03-29

Family

ID=58662599

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018543010A Active JP7043412B2 (ja) 2015-11-03 2016-11-01 疾患の不均一性を特徴づけるための転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞ゲノムプロファイリング

Country Status (9)

Country Link
US (3) US20180321247A1 (https=)
EP (1) EP3371327B1 (https=)
JP (1) JP7043412B2 (https=)
CN (2) CN115341033A (https=)
AU (2) AU2016348401A1 (https=)
CA (1) CA3004150A1 (https=)
EA (1) EA201891085A1 (https=)
IL (1) IL259093A (https=)
WO (1) WO2017079139A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3045918B1 (en) 2009-10-21 2017-12-06 The Scripps Research Institute Method of using non-rare cells to detect rare cells
EA201691496A1 (ru) 2014-01-27 2016-12-30 Эпик Сайенсиз, Инк. Диагностика биомаркеров рака предстательной железы с помощью циркулирующих опухолевых клеток
EA201691682A1 (ru) 2014-02-21 2017-02-28 Эпик Сайенсиз, Инк. Способы анализирования редких циркулирующих в крови клеток
EP3948294B1 (en) * 2019-03-28 2023-06-07 Lundoch Diagnostics AB Use of follistatin in type 2 diabetes risk prediction
US12412272B2 (en) 2019-11-26 2025-09-09 University Of Cincinnati Characterizing intra-site tumor heterogeneity
CN117497044A (zh) * 2022-03-09 2024-02-02 复旦大学 基于单细胞基因组拷贝数变异谱在制造细胞良恶性诊断试剂或检测试剂中的应用
WO2024192141A1 (en) 2023-03-13 2024-09-19 Dana-Farber Cancer Institute, Inc. Treatment of cancers having a drug-resistant mesenchymal cell state

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9671405B2 (en) * 2012-09-19 2017-06-06 Cornell University Identifying taxane sensitivity in prostate cancer patients
DK2981624T3 (da) * 2013-04-05 2020-03-02 Myriad Genetics Inc Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling
US20160266127A1 (en) 2013-09-30 2016-09-15 Peter Kuhn Genotypic and Phenotypic Analysis of Circulating Tumor Cells to Monitor Tumor Evolution in Prostate Cancer Patients
WO2015073896A2 (en) * 2013-11-15 2015-05-21 Psma Development Company, Llc Biomarkers for psma targeted therapy for prostate cancer
CA2937051A1 (en) * 2014-01-17 2015-07-23 Ontario Institute For Cancer Research (Oicr) Biopsy-driven genomic signature for prostate cancer prognosis
EA201691496A1 (ru) * 2014-01-27 2016-12-30 Эпик Сайенсиз, Инк. Диагностика биомаркеров рака предстательной железы с помощью циркулирующих опухолевых клеток
EP3100052B1 (en) * 2014-01-30 2021-03-10 Epic Sciences, Inc. Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapies

Similar Documents

Publication Publication Date Title
JP2018534595A5 (https=)
JP2019502384A5 (https=)
Desitter et al. A new device for rapid isolation by size and characterization of rare circulating tumor cells
Pantel et al. Liquid biopsy and minimal residual disease—latest advances and implications for cure
Laget et al. Technical insights into highly sensitive isolation and molecular characterization of fixed and live circulating tumor cells for early detection of tumor invasion
Marchetti et al. Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment
Jain et al. Molecular pathology of lung cancer cytology specimens: a concise review
Chang et al. DACH1 stimulates shear stress-guided endothelial cell migration and coronary artery growth through the CXCL12–CXCR4 signaling axis
Lohmussaar et al. Human-derived model systems in gynecological cancer research
Blassl et al. Gene expression profiling of single circulating tumor cells in ovarian cancer–Establishment of a multi-marker gene panel
Schmid-Bindert et al. EBUS-TBNA provides highest RNA yield for multiple biomarker testing from routinely obtained small biopsies in non-small cell lung cancer patients-a comparative study of three different minimal invasive sampling methods
EP4484572A3 (en) Identification and use of circulating nucleic acid tumor markers
Steinestel et al. Overexpression of p16INK4a in urothelial carcinoma in situ is a marker for MAPK-mediated epithelial-mesenchymal transition but is not related to human papillomavirus infection
Premasekharan et al. An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer
CN106244553A (zh) 循环肿瘤细胞的分离和检测方法
Regauer et al. Cervical precancers originate from infected proliferating reserve cells: a comparative histologic and genetic study of thin and thick high-grade squamous intraepithelial lesions
Bünger et al. Diversity of assessing circulating tumor cells (CTCs) emphasizes need for standardization: a CTC Guide to design and report trials
EA201891085A1 (ru) Получение геномных профилей отдельных клеток для циркулирующих клеток опухолей (ctc) при метастазирующем заболевании для характеризации гетерогенности заболевания
Lund et al. Initial diagnosis of ALK-positive non-small-cell lung cancer based on analysis of ALK status utilizing droplet digital PCR
JP2018536175A5 (https=)
JP2018535432A5 (https=)
CN104404034A (zh) 利用口腔上皮细胞制作单细胞测序参考品的方法
WO2017053763A3 (en) ANDROGEN RECEPTOR VARIANT 7 AS A BIOMARKER FOR TREATMENT SELECTION IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC)
Wang et al. Optical detection and virotherapy of live metastatic tumor cells in body fluids with vaccinia strains
CN105779635B (zh) 一种基于olfm1基因用于结直肠癌预后判断的试剂盒